Compare Alcon AG (ALC) vs iShares MSCI South Korea ETF (EWY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alcon AG vs iShares MSCI South Korea ETF — how do they compare? Alcon AG trades at $74.32 (market cap $36.44B), while iShares MSCI South Korea ETF trades at $176.77. The key difference: Alcon AG pays a 0.48% dividend while iShares MSCI South Korea ETF pays none, and iShares MSCI South Korea ETF is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ALC | EWY | |
|---|---|---|
Market Cap | $36.44B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $90.12 | $219.20 |
52-Week Low | $62.02 | $71.22 |
Enterprise Value | $40.28B | — |
Dividend Yield | 0.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $73.59, down slightly by 0.05% today, with a bullish technical signal from moving averages and a consensus analyst price target of $86.67 implying 17.8% upside. Recent Q2 2026 earnings beat estimates with EPS of $0.84 versus $0.77 expected, and the company raised its 2026 profitability outlook, driving positive investor sentiment. Revenue growth has been steady, reaching $10.40 billion in 2025, though net income margin dipped to 5.92%.
The outlook is positive given strong earnings beats, raised guidance, and bullish analyst ratings, but risks include elevated P/E of 57.52, high RSI levels suggesting overbought conditions, and margin pressures from rising costs. Institutional ownership trends and recent collaborations, like with RxSight, support growth, yet macroeconomic and competitive factors warrant caution.
EWY, the iShares MSCI South Korea ETF, trades at $175.87, up 7.82% in 24 hours, with a neutral technical signal overall. Recent news highlights volatility in South Korean equities tied to AI and semiconductor stocks, including government support initiatives and foreign capital outflows. The ETF's technical indicators show mixed signals, with bullish moving averages but neutral oscillators, while support and resistance levels suggest near-term consolidation.
The outlook for EWY hinges on South Korea's semiconductor sector recovery and broader market sentiment. Opportunities include potential rebounds from oversold conditions and government-backed chip investments, but risks involve continued volatility from AI trade unwinds and global macroeconomic pressures. Investor caution is warranted amid mixed analyst views and regulatory scrutiny on leveraged ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →
